Skip to main content

CORRECTION article

Front. Immunol., 29 June 2023
Sec. B Cell Biology
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1233632

Corrigendum: Patients’ IgLON5 autoantibodies interfere with IgLON5–protein interactions

This article is a correction to:

  1. Patients’ IgLON5 autoantibodies interfere with IgLON5-protein interactions

    1. Read original article
Jon LandaJon Landa1Ana Beatriz SerafimAna Beatriz Serafim1Carles GaigCarles Gaig2Albert SaizAlbert Saiz2Inga Koneczny,Inga Koneczny3,4Romana Hoftberger,Romana Hoftberger3,4Joan SantamariaJoan Santamaria2Josep Dalmau,,,Josep Dalmau1,2,5,6Francesc GrausFrancesc Graus1Lidia Sabater*Lidia Sabater1*
  • 1Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
  • 2Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain
  • 3Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria
  • 4Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria
  • 5Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States
  • 6Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

A Corrigendum on
Patients’ IgLON5 autoantibodies interfere with IgLON5–protein interactions

by Landa J, Serafim AB, Gaig C, Saiz A, Koneczny I, Hoftberger R, Santamaria J, Dalmau J, Graus F, Sabater L (2023) 14:1151574. doi: 10.3389/fimmu.2023.1151574

In the published article, there was an error in the Funding statement. We did not include that Ana Beatriz Serafim is a recipient of a Doctoral Fellowship grant from Fundação para a Ciência e Tecnologia (FCT) contract number 2022.13121.BD and should be acknowledged. The correct Funding statement appears below.

Funding

This study has been funded by Instituto de Salud Carlos III through the project FIS21/00165 LS, CG (co-funded by the European Regional Development Fund “Investing in your future”). We thank the European Joint Programme on Rare Diseases (EJPRD) for funding a Networking event (contract number 463001015) on IgLON5 disease LS, CG, FG, JD from the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N°825575. IDIBAPS belongs to CERCA (Centres de recerca de Calalunya). IK was funded by a Hertha Firnberg project grant by the Austrian Science Fund (FWF) (Grant No. T996-B30). RH was supported by grants from the Austrian Science Fund FWF: project I4685-B (SYNABS), and DOC 33-B27. The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. ABS thanks Fundação para a Ciência e Tecnologia (FCT) of Portugal for the doctoral fellowship grant number 2022.13121.BD.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: anti-IgLON5 antibody encephalopathy, anti-IgLON5 disease, IgG4, interactome, neurons, IgLON5 antibodies

Citation: Landa J, Serafim AB, Gaig C, Saiz A, Koneczny I, Hoftberger R, Santamaria J, Dalmau J, Graus F and Sabater L (2023) Corrigendum: Patients’ IgLON5 autoantibodies interfere with IgLON5–protein interactions. Front. Immunol. 14:1233632. doi: 10.3389/fimmu.2023.1233632

Received: 02 June 2023; Accepted: 13 June 2023;
Published: 29 June 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Landa, Serafim, Gaig, Saiz, Koneczny, Hoftberger, Santamaria, Dalmau, Graus and Sabater. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lidia Sabater, bGlzYWJhdGVAcmVjZXJjYS5jbGluaWMuY2F0

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.